Older women with osteoporosis who received yearly infusions of a drug that prevents bone loss had far fewer fractures than did peers who didn’t get the drug.
Over 3 years, the women who received zoledronic acid intravenously had about one-third as many spine fractures as did women who received a placebo.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.